Cut

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Paribus: Measure Twice, Cut Once.

Source Node:
Time Stamp: February 25, 2023 1:21 AM - Modified On: February 25, 2023 - Published By:
Source Cluster:
Republished By Plato

Measure Twice, Cut Once It was with a heavy heart that we decided this week to reschedule our MVP launch to early March. It wasn’t a decision we took lightly, knowing full well that it would cause ripples of disappointment throughout our community. As many people know we’ve been working closely with auditors at Hacken to ensure that the MVP is as secure as possible. Our decision to reschedule the launch is to allow the team at Hacken to work directly with our developers next week. Chris, our security advisor